Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.

    Ovarian%20cancer Treatment


    Chemotherapy for Epithelial Ovarian Carcinoma

    • Most patients receive postoperative systemic chemotherapy
    • After surgical cytoreduction, platinum-based chemotherapy is the treatment of choice for patients with advanced epithelial ovarian cancer
      • Monotherapy with Carboplatin every 3 weeks for 6 cycles as adjuvant therapy can be given in early-stage epithelial ovarian cancer; Cisplatin may be an alternative to Carboplatin
    • Observation is recommended in patients with stage IA or IB, grade 1 tumors
      • Survival is >90% with surgical treatment alone
    • Recommendations for the number of cycles of treatment vary with the stage of the disease
      • Earlier stage disease: 3-6 cycles; advanced stages (II-IV): 6 cycles

    Recommended IV Regimens

    • Have different toxicity profiles
      • Paclitaxel followed by Carboplatin given every 3 weeks for 6 cycles
      • Paclitaxel followed by Carboplatin weekly for 18 weeks
      • Docetaxel followed by Carboplatin given every 3 weeks for 6 cycles
      • Dose-dense Paclitaxel on days 1, 8 and 15 plus Carboplatin on day 1 every 3 weeks for 6 cycles
      • Carboplatin plus pegylated liposomal Doxorubicin every 4 weeks for 3-6 cycles
      • Paclitaxel followed by Carboplatin and Bevacizumab every 3 weeks for 5-6 cycles
        • Continue Bevacizumab for up to 12 additional cycles
      • Paclitaxel followed by Carboplatin every 3 weeks for 6 cycles; add Bevacizumab starting cycle 2
        • Continue Bevacizumab up to 22 cycles

    Intraperitoneal (IP) Chemotherapy

    • Allows the possibility of targeting therapy to the site of disease while minimizing systemic toxicities
    • Recommended for all stage III patients with optimally debulked (<1 cm residual) disease
    • Stage II patients may also receive IP chemotherapy
    • Recommended regimen: Paclitaxel on day 1 and 8; Cisplatin on day 2 every 3 weeks for 6 cycles
    • Women unable to complete IP therapy should receive IV therapy
    • Catheter complications, nausea, vomiting, dehydration, or abdominal pain are common reasons for discontinuing the IP treatment
    Borderline Epithelial Ovarian Carcinoma
    • Additional chemotherapeutic option is hormone therapy including aromatase inhibitors (Anastrozole, Letrozole), Leuprolide and Tamoxifen

    Chemotherapy for Germ Cell Ovarian Carcinoma

    • Patients with embryonal or endodermal sinus tumors, stage II-IV dysgerminoma or stage I, grade 2-3 or stage II-IV immature teratoma should receive postoperative chemotherapy with Bleomycin/Etoposide/Cisplatin for 3-4 cycles
    • In some patients with stage IB-III dysgerminoma for whom minimizing toxicity is critical, 3 courses of Etoposide/Carboplatin combination can be used: Carboplatin on day 1 plus Etoposide on days 1-3 every 4 weeks for 3 cycles

    Chemotherapy for Sex Cord Stromal Ovarian Carcinoma

    • For patients with stage II-IV tumors, platinum-based chemotherapy (Bleomycin/Etoposide/Cisplatin or Paclitaxel/Carboplatin) regimens are preferred
    • Platinum-based chemotherapy should be considered for patients with high-risk stage 1 tumors
    • Patients with limited stage II-IV tumors should undergo radiotherapy

    Recurrence Therapy

    Recurrence Therapy for Epithelial Ovarian Carcinoma

    Cytotoxic Therapy

    • Combination platinum-based chemotherapy
      • Preferred for first recurrence in platinum-sensitive patients (ie patients who relapse ≥6 months after initial chemotherapy)
      • The decision regarding which combination to use should be based on the toxicity experienced with primary therapy, patient preference and other factors
      • Preferred agents for platinum-sensitive are:
        • Carboplatin/Paclitaxel
        • Carboplatin/Paclitaxel/Bevacizumab
        • Carboplatin/Gemcitabine
        • Carboplatin/Gemcitabine/Bevacizumab
        • Carboplatin/liposomal Doxorubicin with or without Bevacizumab
        • Cisplatin/Gemcitabine
    • Non-platinum-based agents if platinum-resistant
      • Preferred agents are:
        • Docetaxel
        • Oral Etoposide
        • Gemcitabine
        • Liposomal Doxorubicin
        • Weekly Paclitaxel
        • Topotecan
        • Topotecan/Bevacizumab
        • Weekly Paclitaxel/Bevacizumab
        • Liposomal Doxorubicin/Bevacizumab
        • Oral Cyclophosphamide/Bevacizumab

    Targeted Therapy

    • Bevacizumab is the preferred agent which was shown to slow down the growth of advanced ovarian cancer
      • Can be used as maintenance therapy in patients who were responsive until disease progression or unacceptable toxicity; data on Bevacizumab efficacy as recurrence therapy is limited in patients who had previously received it
    • Olaparib may be given to patients with advanced ovarian cancer with germline BRCA mutation who have undergone treatment with ≥3 lines of chemotherapy with at least 2 courses of platinum-based regimens in previous treatment
    • Rucaparib (platinum-resistant disease) may be given to patients with advanced ovarian cancer with germline and/or somatic BRCA mutation who have undergone treatment with ≥2 lines of chemotherapy 

    Other Agents 

    • Other therapeutic agents for recurrence include Cyclophosphamide, Ifosfamide, Irinotecan, Altretamine, Capecitabine, Doxorubicin, Melphalan, Oxaliplatin, Paclitaxel, albumin-bound Paclitaxel, Pemetrexed, Sorafenib/Topotecan, Vinorelbine, Pazopanib, Carboplatin/Paclitaxel weekly combination for platinum-sensitive disease, hormonal therapy (eg Megestrol acetate, aromatase inhibitors, Leuprolide acetate, Tamoxifen)
    • Other agents to be considered in certain circumstances:
      • Mucinous carcinoma: 5-FU/Leucovorin/Oxaliplatin with or without Bevacizumab & Capecitabine/Oxaliplatin with or without Bevacizumab
      • Clear cell carcinoma: Irinotecan/Cisplatin
      • NTRK gene-fusion positive carcinoma: Entrectinib, Larotrectinib
      • Confirmed taxane hypersensitivity: Carboplatin/albumin-bound Paclitaxel
      • Low-grade serous carcinoma: Fulvestrant
      • Microsatellite instability-high [MSI-H] or mismatch, repair-deficient [dMMR] solid tumors: Pembrolizumab

    Recurrence Therapy for Germ Cell Ovarian Carcinoma

    • Recommended in patients with recurrent or residual disease after multiple chemotherapeutic regimens for whom no curative options are considered possible
    • Options may include Paclitaxel/Ifosfamide/Cisplatin (TIP), Vincristine/Dactinomycin/Cyclophosphamide (VAC), Vinblastine/Ifosfamide/Cisplatin (VeIP), Etoposide/Ifosfamide/Cisplatin (VIP), Cisplatin/Etoposide, Docetaxel/Carboplatin, Paclitaxel/Carboplatin, Paclitaxel/Gemcitabine, Paclitaxel/Ifosfamide, Docetaxel, Paclitaxel, high-dose chemotherapy, radiation therapy, or supportive care
      •  Combination chemotherapy is not recommended in patients with recurrent or residual disease who have no curative options

    Recurrence Therapy for Sex Cord-Stromal Ovarian Carcinoma

    • Acceptable chemotherapy regimens include Docetaxel, Paclitaxel, Paclitaxel/Ifosfamide, Paclitaxel/Carboplatin, VAC, Tamoxifen, Bevacizumab, aromatase inhibitors, radiation therapy, or supportive care
      • Leuprolide or Bevacizumab may be used for granulosa cell tumors
    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
    Sign In To Download
    Editor's Recommendations
    Most Read Articles
    01 Dec 2020
    Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
    Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
    Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
    Tristan Manalac, Yesterday
    While antibody titres against SARS-CoV-2 wane with time, the immune system is capable of producing memory B-cells that can last for at least 6 months after infection, suggesting that the body will be able to protect itself in the case of re-exposure, according to a new study.
    Jairia Dela Cruz, 5 days ago
    Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.